Drug Profile
Research programme: anticancer antibodies - ARIUS/PDL BioPharma
Latest Information Update: 10 Sep 2008
Price :
$50
*
At a glance
- Originator ARIUS Research
- Class Monoclonal antibodies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 29 Nov 2006 Development is still ongoing
- 09 Jan 2006 Protein Design Labs is now called PDL BioPharma
- 24 Nov 2005 The research project has met another objective and satisfied the next requirement for licensing by PDL